|
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
Sep 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy |
Sep 2024 |
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
|
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
Expert Review of Clinical Pharmacology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version |
Sep 2024 |
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
|
How we diagnose Myelodysplastic syndromes |
Sep 2024 |
Frontiers in Oncology |
Myelodysplastic Syndromes (MDS) |
|
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
Sep 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
Sep 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
